Wegovy injections are FDA approved for adults and children 12 years and older with a body mass index of 30 or more, or patients with additional conditions, such as high cholesterol, hypertension, sleep apnea, type 2 diabetes, heart disease, or other chronic metabolic illnesses, who have body mass index of 27 or more
By analyzing data from three clinical trials that tested the effect of semaglutide versus placebo on people with MASLD or MASH
Third, lipolysis becomes more efficient, allowing stored fat to be mobilized and used for energy
Each person who received retatrutide started with a 2 mg dose, with amounts increasing every four weeks until they reached their targeted dose
Weight loss and improved blood sugar control are two of the most effective ways to protect the kidneys from chronic disease